Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP9X | Q93008 | 10/20 | 0.73 |
| ▸ | USP24 | Q9UPU5 | 1/20 | 0.73 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.44 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18017555 | 0.92 | USP9X (0.86) | USP9XUSP24UCHL1USP5KDM4E | |
| SCHEMBL18017557 | 0.86 | USP9X (0.86) | USP9XUSP24UCHL1USP5KDM4E | |
| SCHEMBL18017556 | 0.85 | USP9X (0.75) | USP9XUSP24AVPR1BKDM4EPOLB | |
| SCHEMBL16647263 | 0.85 | USP9X (1.00) | USP9XUSP24UCHL1USP5ACACB | |
| SCHEMBL17986430 | 0.85 | USP9X (1.00) | USP9XUSP24UCHL1USP5ACACB | |
| SCHEMBL18017563 | 0.84 | USP9X (0.53) | USP9XUSP24UCHL1USP5ROCK2 | |
| SCHEMBL18017567 | 0.84 | USP9X (0.74) | USP9XUSP24UCHL1USP5KMT2A | |
| SCHEMBL18017561 | 0.83 | USP9X (0.70) | USP9XUSP24KDM4EPOLBESR1 | |
| SCHEMBL18017560 | 0.79 | USP9X (0.87) | USP9XUSP24UCHL1USP5AVPR1B | |
| SCHEMBL16647252 | 0.78 | USP9X (0.88) | USP9XUSP24KDM4EACACBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868736-B2 | Deubiquitinase inhibitors and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160237082-A1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237082-A1 | DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME | USP1, UCHL1, USP2 | USP9X 33/4885USP24 29/4885UCHL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.